<font color="blue">Plasma_4</font> <font color="blue">AGE_4</font> <font color="blue">-_4</font> <font color="blue">peptides_4</font> <font color="blue">and_4</font> <font color="blue">C_4</font> <font color="blue">-_4</font> <font color="blue">peptide_4</font> in <font color="blue">early_1</font> <font color="blue">-_1</font> <font color="blue">stage_1</font> <font color="blue">diabetic_1</font> <font color="blue">nephropathy_1</font> patients on thiamine and pyridoxine therapy . 
<br>
<br> AIM The aim of the study was to evaluate <font color="blue">circulatory_3</font> <font color="blue">AGE_4</font> <font color="blue">-_4</font> <font color="blue">peptide_4</font> <font color="blue">levels_3</font> in diabetic nephropathy and to observe <font color="blue">the_1</font> <font color="blue">effects_2</font> <font color="blue">of_2</font> <font color="blue">thiamine_2</font> <font color="blue">(_2</font> <font color="blue">vitamin_2</font> <font color="blue">B1_2</font> <font color="blue">)_2</font> <font color="blue">and_2</font> <font color="blue">pyridoxine_2</font> <font color="blue">(_2</font> <font color="blue">vitamin_2</font> <font color="blue">B6_2</font> <font color="blue">)_2</font> <font color="blue">therapy_2</font> <font color="blue">._2</font> 
<br> METHODS Type 2 diabetic patients ( N.=57 ) were divided into two groups as " with nephropathy " ( N.=27 ) and " without nephropathy " ( N.=30 ) . Diabetic nephropathy patients were treated with either B6 ( N.=12 ) ( 250 mg / day ) or B1+B6 ( N.=15 ) ( 250 mg / day , each ) for five months . At the beginning and the end of the experimentation period , <font color="blue">glucose_4</font> <font color="blue">,_4</font> <font color="blue">HbA1c_4</font> <font color="blue">,_4</font> <font color="blue">triglyceride_4</font> <font color="blue">,_4</font> <font color="blue">cholesterol_4</font> <font color="blue">,_4</font> <font color="blue">insulin_4</font> <font color="blue">,_4</font> <font color="blue">C_4</font> <font color="blue">-_4</font> <font color="blue">peptide_4</font> <font color="blue">,_4</font> <font color="blue">thiamine_4</font> <font color="blue">pyrophosphate_4</font> <font color="blue">,_4</font> <font color="blue">pyridoxal_4</font> <font color="blue">phosphate_4</font> <font color="blue">and_4</font> <font color="blue">AGE-_4</font> <font color="blue">peptides_4</font> were measured . 
<br> RESULTS <font color="blue">AGE_3</font> <font color="blue">-_3</font> <font color="blue">peptides_4</font> were higher in the diabetic group with nephropathy than without nephropathy ( P=0.005 ) . Within five months <font color="blue">AGE_3</font> <font color="blue">-_3</font> <font color="blue">peptides_3</font> increased in the diabetic group without nephropathy ( P=0.042 ) but not in the group with nephropathy treated either with B1+B6 or B6 . In B6 treated group a substantial decrease was observed in <font color="blue">HbA1c_3</font> ( P=0.033 ) . B1+B6 or B6 treatment both caused an increase in <font color="blue">C_4</font> <font color="blue">-_4</font> <font color="blue">peptide_4</font> ( P=0.006 , P=0.004 ) . 
<br> CONCLUSION Among the parameters measured , <font color="blue">plasma_4</font> <font color="blue">AGE_4</font> <font color="blue">-_4</font> <font color="blue">peptides_4</font> was the only parameter found to be higher in type 2 diabetes mellitus patients " with nephropathy " than " without nephropathy " . However , patients with nephropathy treated with B1+B6 or B6 did not display any further increase in <font color="blue">AGE_3</font> <font color="blue">-_3</font> <font color="blue">peptides_3</font> within five months . Both of the treatments caused an increase in <font color="blue">C_3</font> <font color="blue">-_3</font> <font color="blue">peptide_3</font> <font color="blue">._3</font>